Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.

Methods, kits, and compositions are provided herein for determining the eligibility of a subject to receive an anti-CD47 treatment based on a presence or absence of B-cells in the subject, and subsequently treating the eligible subject with the anti-CD47 treatment alone or in combination with one or more additional agent such as an anti-CD20 antibody.

A method for the evaluation of a hydrolyzed allergen preparation comprising the steps of: bringing the preparation into contact with a human blood sample—measuring proliferation of IL10 producing regulatory B-cells, wherein proliferation indicates suitability of the preparation.

The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.

This invention provides methods to evaluate therapeutic efficacy of therapeutic monoclonal antibodies.

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.

The microfluidic platform device of the claimed invention makes use of a high throughput lab-on-a-chip format to determine the functional profile of antibodies elicited by infection or vaccination against infection for any pathogen. It can be used to evaluate vaccines, evaluate whether vaccinated individuals show indices of protection, determine whether individuals display resistance or susceptibility to infection, discover new vaccine antigens, discover and test therapeutic interventions, or evaluate mechanisms of disease.

Isolated immune cells having TCR+, CD8+, Nk1.1+, PLZF+, CD161+, and optionally having one or more of CD11c+, CD137+ CD244+ or one or more of NK-inhibitory receptors, and methods of obtaining and using those cells, as well as methods to inhibit or enhance those cells in a mammal are provided.

The present application provides a group of human immortalized B lymphocyte cell lines and use thereof, and specifically provides a combination of four closely related immortalized lymphocyte cell lines. The combination can be used as a standard product for accuracy evaluation of a detection platform. When the four closely related immortalized lymphocyte cell lines are used as standard products for epigenome, transcriptome, proteome, and metabolome, an intrinsic magnitude difference gradient can be formed to evaluate the sensitivity of histological detection.